| 1 |
31066225 | Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment. | 2019 Sep |
1 |
| 2 |
29896193 | Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment. | 2018 |
1 |
| 3 |
28258191 | Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients. | 2017 Apr 15 |
1 |
| 4 |
28391741 | Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? | 2017 Aug |
1 |
| 5 |
26767188 | Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. | 2016 Feb |
1 |
| 6 |
26108267 | The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis. | 2015 Jul |
2 |
| 7 |
9767281 | The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. | 1998 Sep |
1 |